Cargando…

Tumor necrosis factor receptor family costimulation increases regulatory T‐cell activation and function via NF‐κB

Several drugs targeting members of the TNF superfamily or TNF receptor superfamily (TNFRSF) are widely used in medicine or are currently being tested in therapeutic trials. However, their mechanism of action remains poorly understood. Here, we explored the effects of TNFRSF co‐stimulation on murine...

Descripción completa

Detalles Bibliográficos
Autores principales: Lubrano di Ricco, Martina, Ronin, Emilie, Collares, Davi, Divoux, Jordane, Grégoire, Sylvie, Wajant, Harald, Gomes, Tomás, Grinberg‐Bleyer, Yenkel, Baud, Véronique, Marodon, Gilles, Salomon, Benoît L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7383872/
https://www.ncbi.nlm.nih.gov/pubmed/32012260
http://dx.doi.org/10.1002/eji.201948393
Descripción
Sumario:Several drugs targeting members of the TNF superfamily or TNF receptor superfamily (TNFRSF) are widely used in medicine or are currently being tested in therapeutic trials. However, their mechanism of action remains poorly understood. Here, we explored the effects of TNFRSF co‐stimulation on murine Foxp3(+) regulatory T cell (Treg) biology, as they are pivotal modulators of immune responses. We show that engagement of TNFR2, 4‐1BB, GITR, and DR3, but not OX40, increases Treg proliferation and survival. Triggering these TNFRSF in Tregs induces similar changes in gene expression patterns, suggesting that they engage common signal transduction pathways. Among them, we identified a major role of canonical NF‐κB. Importantly, TNFRSF co‐stimulation improves the ability of Tregs to suppress colitis. Our data demonstrate that stimulation of discrete TNFRSF members enhances Treg activation and function through a shared mechanism. Consequently, therapeutic effects of drugs targeting TNFRSF or their ligands may be mediated by their effect on Tregs.